Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If they did, they would buy at this level about 3x cheaper than last time CEO bought unless he isn't the most knowledgeable on the company's future performance.
Wonder why management isn't buying at these prices? These are almost at historic lows for the management team. Several years running the company. Zero value added according to the stock price.
Chart is historical. Completely ignores inept management's future destruction.
That is the issue - Nasrat doesn't have a solid plan. Never did. When asked about return on investment, market share, drug prices, etc he was clueless and left it "up to the experts".
No leader, especially a CEO, makes huge investments without basic financial fundamentals and yet the expense spigot keeps on flowing.
They will both be equivalent for Elite at 0 without removal of the warning letter.
IR at this company is just another addition to the joke.
That is a step in the right direction, but last time I checked approvals don't pay bills. Decent partner with sales & marketing infrastructure would help.
No, not just market makers. Much more than that.
You can see that value in today's share price spike. Lol
Fascinating article & results of overcoming opiate addiction via herbal plant, kratom. Little is known, but no incentive for BP to pursue.
http://www.cnn.com/2017/10/26/health/opioid-crisis-kratom-potential/index.html
Sales are pitiful before and after the "drop". To have a drop, you need to actually have sales first. Elite is still a long way away from that point.
The premise that Elite would be profitable if they stopped R&D was true in the past, but probably not accurate moving forward. Even if it were true don't think for a second there would be a forward multiple. The sales for the company are pitiful and will continue to even worsen until we hear otherwise.
Partner couldn't stop those deals. Until this company's story changes and there exists institutional holding, Nasrat will pull the same crap all day long.
Very astute comment on the partnership vs dilution. One benefit is that Elite is still scrapped for cash and the CEO creates favors for the company with these crappy self-serving deals.
Leveraging volume is what makes them cheap. Non-addictive quality for pain management would absolutely destroy opiate industry.
* do or die, not donor
Elite is in a donor die position. If Nasrat leaves he takes all his ownership with him current and future beyond current authorized shares. This is relationship will not end well.
At this point, Nasrat doesn't have the ability to do so.
Quiet period just means they can't talk to individual investors. Doesn't mean they can't provide a public update on any news.
This stock hasn't had legs for the last 18 months. "No one can stop us" BS dealt an FDA kick to the face.
Looks like FDA is clearly showing who has all the leverage despite what some posters here say time and time again.
That is what Scottrade shows too.
I think there is some truth to this. We know Methadone sales are disappearing. No insight given to the tail of this so could be gone entirely for all we know. Trimipramine may be the big sales driver now. Huge win there. lol
Until warning letter lifted, FDA submissions have zero value. Even then, FDA approvals don't pay rent.
Um. Reality sucks, but 0.05 can't get much closer to 0.05.
Sir Nasrat, knighted as King of the Round Billion
I would imagine some nice stop loss triggers were hit on the way down
My guess is a market order slip up vs limit order. Or could just be disgusted shareholders cashing out.
All while leaving out fed BE results, which forced the company to halt the program and go back to square 1 - material science stage. No telling if they will advance further for IR, ever.
Trump's Opiate Plan:
Announced access to public health emergency funds for opiate crisis! Woohoo! What's that mean? Zip. Nada. There is nothing in that bank account except for $57,000.
http://www.npr.org/sections/health-shots/2016/06/03/480565668/a-permanent-fund-to-help-fight-zika-exists-but-its-empty
Umm no. I mentioned a non-addictive just as effective product being developed in Boston area by a university a couple months ago. No addictive qualities. Entering PIII trials.
At this rate, it may get acceptance well before Elite's warning letter is lifted.
ADFs would shoot themselves in the foot by lowering their volume on which they are paid. Until it becomes forced legislatively I don't see it happening near term. This is what sets them up for real sales, to become a real company. No sales even with approvals becomes dead in the water.
FDA approval does not signify PBM backing.
How does this solve the lack of PBM backing? Are you assuming the pressure at some point will be so great that they will have no choice, but to do so?
Embarrassed or not they must report and they will continue to do so. They aren't on the verge of bankruptcy since they went equity dilution vs debt.
Embarrassment only continues the lack of open Q&A.
Completely missed the point. If you didn't sell all those 0.06's you missed out on that 10 fold return. You have mentioned time and time again you are still holding them therefore your 10-bagger completely dissolved.
I think you are right, but don't think it will hold until real partnerships and sales are realized. It would create a set up for such...
No, the point was why call X bagger over and over if it was never realized. Beyond stupid.
Interesting article. Uncertainty around ADT guidelines only raises more eyebrows for Elite being in the thick of it.
Happy to see Gottlieb make such sweeping changes as they should have been done years ago.
Yes. It is after the fiscal period before an earnings call. This is the basic definition of a quiet period.
Along with - the stock price won't go below 0.30. Reality bites.